Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics

Current treatment practice may delay optimal intervention, potentially leading to missed therapeutic windows. A significant proportion of respondents expressed a preference for earlier biologic intervention, especially in cases of severe disease or frequent flares. The findings underscore the need for a consensus statement defining upgrade criteria for biologics as a first-line therapy, potentially improving patient outcomes and reducing healthcare burdens.

Authors

Institutions

Publication Details

Journal
Journal of the European Academy of Dermatology and Venereology
Published
2025-11-13
DOI
https://doi.org/10.1111/jdv.70118
Citations
4
Primary Topic
Hidradenitis Suppurativa and Treatments
Type
article
Field-Weighted Citation Impact
8.02

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics

Thrasyvoulos Tzellos, K. Glasenhardt, Angelo Valerio Marzano, Christos C. Zouboulis et al.
4 citations
Journal of the European Academy of Dermatology and Venereology
Hidradenitis Suppurativa and Treatments
8.02
article

Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics

Thrasyvoulos Tzellos, K. Glasenhardt, Angelo Valerio Marzano, Christos C. Zouboulis, Evangelos J. Giamarellos‐Bourboulis, Niamh Kearney, Joana Cabete, Dillon Mintoff, Giovanni Damiani, Linnea Thorlacius, Georgios Nikolakis, Vesta Kučinskienė, John R Ingram, Piotr K. Krajewski, Łukasz Matusiak, Aikaterini Ι. Liakou, Antonio Martorell, A. Häfner, Valentina Dini, Hans Christian Ring, Vaiva Jarienè, Farida Benhadou, Sezer Şahin, Falk G. Bechara, Alejandro Molina‐Leyva, Raffaele Dante Caposiena, V. del Mármol, Flavia Manzo Margiotta, Ditte Marie Lindhardt Saunte, Hessel H. van der Zee, Marco Romanelli, Kelsey R. van Straalen, E. Hristakieva, Francesca Prignano, Erkan Alpsoy, Natalia Kirsten, Tadas Raudonis, Gregor B. E. Jemec, Monika Arenbergerová, Philippe Guillem, Brian Kirby, Maia Delage Toriel
article en
4 citations

Abstract

Current treatment practice may delay optimal intervention, potentially leading to missed therapeutic windows. A significant proportion of respondents expressed a preference for earlier biologic intervention, especially in cases of severe disease or frequent flares. The findings underscore the need for a consensus statement defining upgrade criteria for biologics as a first-line therapy, potentially improving patient outcomes and reducing healthcare burdens.

Journal of the European Academy of Dermatology and VenereologyVol. 40(4)
University College Dublin (IE), Wrocław University of Science and Technology (PL), University of Copenhagen (DK), Our Lady of Lourdes Hospital (IE), Université Libre de Bruxelles (BE), University of Trieste (IT), Institut Pasteur (FR), Scuola Superiore Sant'Anna (IT), Trakia University (BG), Vilnius University (LT), Universidad de Granada (ES), University of Milan (IT), Akdeniz University (TR), National and Kapodistrian University of Athens (GR), Charles University (CZ), University of Szeged (HU), University Hospitals of the Ruhr-University of Bochum (DE), Tel Aviv Sourasky Medical Center (IL), Frederiksberg Hospital (DK), Mater Dei Hospital (MT), Nordland Hospital Trust (NO), Erasmus MC (NL), Erasmus Hospital (BE), Aarhus University Hospital (DK), Hospital of Lithuanian University of Health Sciences Kaunas Clinics (LT), Gentofte Hospital (DK), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), LMU Klinikum (DE), Wroclaw Medical University (PL), HIA du Val-de-Grâce à Paris (FR), Zealand University Hospital (DK), Ospedale Santa Chiara (IT), Städtisches Klinikum Dessau (DE), St. Vincent's University Hospital (IE), Hospital Universitario Virgen de las Nieves (ES), Hospital de Manises (ES), Andreas Sygros Hospital (GR), Società Italiana di Reumatologia (IT), Hôpitaux Iris Sud (BE), Hospital Santo António dos Capuchos (PT), Medizinische Hochschule Brandenburg Theodor Fontane (DE), University Hospital Kralovske Vinohrady (CZ), University of Florence (IT), AGH University of Krakow (PL), Cardiff University (GB), Ludwig-Maximilians-Universität München (DE), Ruhr University Bochum (DE), Gazi University (TR)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Sanofi, Celgene, Incyte, Celltrion, Insmed, National and Kapodistrian University of Athens, Galderma, Swedish Orphan Biovitrum, LEO Pharma, UCB Pharma, Cilag
Openalex Percentile: Top 2%
Hidradenitis Suppurativa and Treatments
8.02
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.